Suzanne Holden, Vice President, Corporate Accounts & Country Leader United Kingdom at Thermo Fisher Scientific, shares her thoughts on why she is excited about the research and investment in predictive genomics. Read this short article that discusses: addressing unmet needs, improving patient outcomes; polygenic risk scores - stratifying the population and from drug discovery to clinical though validation: 'The future, now: Revolutionising disease prevention through predictive genomics'
London, July 3rd - Kadans Science Partner will add Harrow House in Oxford, UK to its Pan-European portfolio. The asset will be acquired from Oxford Biomedica in a sale and lease back transaction. Harrow House is a purpose-built manufacturing facility which will be leased back, in its entirety, to Oxford Biomedica. Oxford Biomedica is a quality and innovation-led viral vector CDMO, providing development and manufacturing expertise to some of the world’s most innovative pharmaceutical and biotechnology companies.
Oxford is a global centre of excellence in life science innovation. The…
Stevenage Bioscience Catalyst is a renowned hub for life sciences in the UK and is recognised as being on par with other established EU clusters specialising in cell and gene therapy.
Read more about how their exciting developments and opportunities for collaboration is making them a centre for excellence.
- PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments for millions of women worldwide.
Oxford, UK, 29 June 2023 – PrecisionLife, a leading techbio company driving precision medicine in complex chronic diseases, announced today a data access agreement with the University of Oxford to license the Oxford Endometriosis Gene (OXEGENE) dataset with the aim to develop new personalised treatments for endometriosis patients.
Endometriosis is a chronic disease associated…
Planning Submitted at 4 Brandon Road, Kings Cross
Designed collaboratively with the Kadans in-house team and DMA, the building sits adjacent to the existing 5-10 Brandon Road to provide a range of complimentary spaces.
The proposal at 4 Brandon Road is five storeys of flexible lab space with the addition of basement and roof plant. Designed with adaptability at the core, the floorplates are arranged on a regular grid to minimise vibration and maximise usable space.
The double-height entrance creates a sense of arrival and animates the ground floor accommodation. The…
AMSBIO has published a blog about Dr. Satoshi Okamoto’s groundbreaking research on the production of induced pluripotent stem cells (iPSC)-derived liver organoids, and their significant potential in clinical research trials.
The primary objective of Dr. Okamoto's research program at the Yokohama City University Graduate School's Department of Regenerative Medicine was to achieve large-scale, stable production of clinical-grade liver organoids. These organoids have the potential to revolutionize treatment for liver diseases and could be administered to patients with liver diseases as a…
Patents further strengthen Group’s extensive patent portfolio protecting its Arestat™ technology and innovative insulin products, AT278 and AT247
Cambridge, UK, 27 June 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a key patent (EP3518892), protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247. In addition, the China National Intellectual Property Administration has granted a further patent (CN110582285)…
Cambridge, UK, June 22, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023.
ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein which is thought to have a key role in Alzheimer’s disease. Studies have found that higher expression of CD33 is associated with more advanced…
- Data presented at the American Diabetes Association 83rd Scientific Sessions
- AT247 delivers significantly accelerated insulin absorption and early exposure (PK profile) compared with NovoLog® and Fiasp®
- Further supports potential to enable more effective disease management for people with Type I diabetes via fully automated closed loop insulin pump delivery (artificial pancreas)
Cambridge, UK, 26 June 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that positive results from its second Phase…